×
ASH 2020 Annual Meeting and Exposition
https://www.hematology.org/meetings/annual-meeting

Attend the world’s most comprehensive hematology event of the year for invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.

ASH 2020 Schedule and Program
https://www.hematology.org/meetings/annual-meeting/schedule-and-program

The final program, personal scheduler, oral and poster sessions, scientific program, education program, general sessions, special-interest sessions, trainee activities, policy and practice, global capacity-building showcase, acknowledgments, related content

Associations between hematology/oncology fellows' training and mentorship experiences a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855099
Blood Advances; Masselink LE, Erikson CE et. al.

Nov 7th, 2019 - As the adult hematology and oncology fellowship training pathways have merged in the United States and concerns have arisen about the aging of practicing hematologists, the American Society of Hematology and hematology education leaders are looking to improve their understanding of the factors that contribute to fellows' plans to enter hematology-only careers. With the support of the American S...

Teetering on a liver's edge: a case report highlighting clinical decision-making in thr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836470
BMC Cancer; Yan A, Erdman L et. al.

Nov 6th, 2019 - This report illustrates the importance of a detailed history and physical exam and careful analysis of hematologic parameters when diagnosing ITP. This case demonstrates that even with subtle deviations from typical ITP findings one must promptly reevaluate the diagnosis. This case also highlights the importance of peripheral smear review by an expert in pediatric hematopathology. A previously ...

ASH Announces Three New Executive Committee Members, Free Childcare at the 2019 ASH Annual Meeting, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-announces-three-new-executive-committee-members-free-childcare-2019-ash-annual-meeting/

Nov 1st, 2019 - Jane N. Winter, MD, Vice President Alison Loren, MD, Councillor Bob Löwenberg, MD, PhD, Councillor Congratulations to ASH’s Three New Executive Committee Members The American Society of Hematology (ASH) has announced the election of three new members to its Executive Committee for terms beginning after the 2019 ASH Annual Meeting in December. Jane N. Winter, MD, will serve a one-year term as vi...

Remembering Thomas P. Stossel, CPRIT Awards $136 Million in 71 New Grants, and more
https://www.ashclinicalnews.org/news/the-society-pages/remembering-thomas-p-stossel-cprit-awards-136-million-71-new-grants/

Nov 1st, 2019 - Remembering Thomas P. Stossel (1941 – 2019) Thomas P. Stossel, MD, former president of the American Society of Hematology (ASH), passed away unexpectedly on September 29. Born in Chicago in 1941, Dr. Stossel grew up in Wilmette, Illinois. He attended Princeton University and Harvard Medical School before completing his internal medicine training at Massachusetts General Hospital and his hematol...

ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline R...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849945
Blood Advances; Luo X, Feurstein S et. al.

Oct 27th, 2019 - Standardized variant curation is essential for clinical care recommendations for patients with inherited disorders. Clinical Genome Resource (ClinGen) variant curation expert panels are developing disease-associated gene specifications using the 2015 American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines to reduce curation discrepancies...

Zanetta Lamar, MD, Joins Florida Cancer Specialists
https://ascopost.com/issues/october-25-2019/zanetta-lamar-md-joins-florida-cancer-specialists/

Oct 24th, 2019 - Florida Cancer Specialists & Research Institute (FCS) welcomes Zanetta Lamar, MD, to the statewide practice. She is practicing medical oncology and hematology in the Naples Goodlette office. Zanetta Lamar, MD After earning her medical degree with honors from Meharry Medical College in Nashville, Dr. -Lamar completed her internal medicine internship and residency, as well as her hematology and o...

Metabolomic profiling identifies pathways associated with minimal residual disease in c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838385
EBioMedicine Schraw JM, Junco JJ et. al.

Oct 21st, 2019 - End-induction minimal residual disease (MRD) is the strongest predictor of relapse in paediatric acute lymphoblastic leukaemia (ALL), but an understanding of the biological pathways underlying early treatment response remains elusive. We hypothesized that metabolomic profiling of diagnostic bone marrow plasma could provide insights into the underlying biology of early treatment response and inf...

Pulmonary Embolism (PE) Guidelines
https://emedicine.medscape.com/article/300901-guidelines

Oct 15th, 2019 - Guidelines Summary Guidelines for the diagnosis and management of pulmonary embolism (PE) have been issued by the following organizations: American Academy of Family Physicians (AAFP)/American College of Physicians (ACP) [4] American College of Physicians (ACP) [111] American College of Emergency Physicians (ACEP) [112] American College of Radiology (ACR) [69] American College of Chest Physicia...

Venous Thromboembolism (VTE) Workup
https://emedicine.medscape.com/article/1267714-workup

Oct 14th, 2019 - Approach Considerations Diagnosis of venous thromboembolism (VTE) may include laboratory tests, imaging (eg, chest radiography, computed tomography [CT], angiography, ultrasonography [US], echocardiography, and ventilation-perfusion [V/Q] scanning) and tests such as plethysmography and electrocardiography (ECG). Guidelines for diagnosis of VTE have been published by the American Society of Hema...

Xarelto OK'd for VTE Prevention in Acute Medical Illness
https://www.medpagetoday.com/cardiology/venousthrombosis/82720

Oct 14th, 2019 - The FDA approved rivaroxaban (Xarelto) to prevent venous thromboembolism (VTE) and related deaths for at-risk acutely ill medical patients not at high risk of bleeding, Janssen announced Monday. The approval was for the hospitalization and through discharge to a total recommended duration of 31 to 39 days. "Rather than facing daily injections with older anticoagulants, patients now have a new o...

Inhaled nitric oxide for treating pain crises in people with sickle cell disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788324
The Cochrane Database of Systematic Reviews; Aboursheid T, Albaroudi O et. al.

Oct 11th, 2019 - In people with sickle cell disease, sickled red blood cells cause the occlusion of small blood vessels which presents as episodes of severe pain known as pain crises or vaso-occlusive crises. The pain can occur in the bones, chest, or other parts of the body, and may last several hours to days. Pain relief during crises includes both pharmacologic and non-pharmacologic treatments. The efficacy ...

Anemia management in cancer patients with chronic kidney disease.
https://doi.org/10.1111/sdi.12841
Seminars in Dialysis REFERENCES; Latcha S

Oct 9th, 2019 - Cancer and kidney disease are linked by causality and comorbidities. Observational data show an increased risk of malignancy as renal function declines. Erythropoietin stimulating agents (ESAs), which are the cornerstone therapy for anemia patients with chronic kidney disease and cancer, are associated with increased risks for cancer, cancer-related mortality, progression of disease, and thromb...

Hypertension & CV Adverse Events With Ibrutinib in 'Real World'
https://www.medscape.com/viewarticle/919574

Oct 7th, 2019 - Since its approval in 2016, ibrutinib (Imbruvica, Pharmacyclics) has rapidly changed the treatment landscape of chronic lymphocytic leukemia (CLL) and several rarer hematologic malignancies. However, emerging real-world data are now suggesting caution, owing to increased risk for hypertension and other cardiovascular adverse events. A study published online October 3 in Blood reported a retrosp...

ASH Clinical News Now Available on the ASH Publications App, ABIM Changing Maintenance of Certification Standards, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-clinical-news-now-available-ash-publications-app-abim-changing-maintenance-certification-standards/

Oct 1st, 2019 - ASH Clinical News Now Available on the ASH Publications App The American Society of Hematology (ASH) Publications app provides access to content from Blood, Blood Advances, The Hematologist, and, now, ASH Clinical News, plus great features that allow readers to: Save articles for offline reading Take notes on specific articles Access Blood articles ahead of publication with First Edition Get no...

Remembering Stanley Schrier, John Hansen, and more
https://www.ashclinicalnews.org/news/the-society-pages/remembering-stanley-schrier-john-hansen/

Oct 1st, 2019 - Stanley Schrier, MD Remembering Stanley Schrier (1929 – 2019) Stanley Schrier, MD, a former American Society of Hematology (ASH) president who spent nearly 60 years at Stanford University’s Department of Medicine, passed away on August 16. In 1954, Dr. Schrier graduated from Johns Hopkins University School of Medicine, where he remained for his internship before moving to the universities of Mi...

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545304
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting.|2019||therapeutic use,therapeutic use,therapeutic use,therapy,drug therapy,therapy,therapy,

Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545307
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.|2019||adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,therapy,drug therapy,genetics,therapy,adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545309
Clinical Advances in Hematology & Oncology : H&O;

Sep 23rd, 2019 - Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting.|2019||therapeutic use,drug therapy,therapeutic use,adverse effects,therapeutic use,drug therapy,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,adverse effects,therapeutic use,therapeutic use,

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545305
Clinical Advances in Hematology & Oncology : H&O; Haverkos B

Sep 22nd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A hematologist's perspective.|2019|Haverkos B,|

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology An...
https://www.ncbi.nlm.nih.gov/pubmed/31545306
Clinical Advances in Hematology & Oncology : H&O; Geskin LJ

Sep 22nd, 2019 - Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A dermatologist's perspective.|2019|Geskin LJ,|

Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545308
Clinical Advances in Hematology & Oncology : H&O; O'Brien SM

Sep 22nd, 2019 - Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting: commentary.|2019|O'Brien SM,|

Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology...
https://www.ncbi.nlm.nih.gov/pubmed/31545310
Clinical Advances in Hematology & Oncology : H&O; Mesa RA

Sep 22nd, 2019 - Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting: commentary.|2019|Mesa RA,|

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942175
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation; Holstein SA, Al-Kadhimi Z et. al.

Sep 18th, 2019 - The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discus...

Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas
https://ascopost.com/issues/september-10-2019/update-on-fda-approved-car-t-cell-gene-therapy-for-b-cell-lymphomas/

Sep 9th, 2019 - Syed Ali Abutalib, MD David L. Porter, MD On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, primary...

Valoctocogene Roxaparvovec Continues to Improve Bleeding Outcomes in Patients with Hemophilia A
https://www.ashclinicalnews.org/on-location/other-meetings/valoctocogene-roxaparvovec-continues-improve-bleeding-outcomes-patients-hemophilia/

Sep 1st, 2019 - In three-year follow-up results from an ongoing phase I/II study of patients with hemophilia A, valoctocogene roxaparvovec gene therapy significantly reduced annual bleeding rates (ABRs) and increased factor VIII (FVIII) activity levels. Lead author John Pasi, MBChB, PhD, from Barts and the London School of Medicine and Dentistry, presented the findings at the 2019 Congress of the International...

ASH Sickle Cell Initiative Wins Top ASAE Prize, ASH-a-Palooza 2019 Announced, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-sickle-cell-initiative-wins-top-asae-prize-ash-palooza-2019-announced/

Sep 1st, 2019 - ASH Sickle Cell Disease Initiative Wins Top ASAE Prize The American Society of Hematology (ASH) is proud to have been named a 2019 Power of A Summit Award winner for the Society’s multifaceted Sickle Cell Disease (SCD) Initiative. The Power of A Summit Award, given annually by the American Society of Association Executives (ASAE), recognizes the association community’s valuable contributions on...

ABIM: Self-paced MOC pathway under development
https://www.mdedge.com/internalmedicine/article/207353/business-medicine/abim-self-paced-moc-pathway-under-development/page/0/1?channel=27980

Aug 31st, 2019 - Alan Lichtin, MD, chair of the MOC working group for the American Society of Hematology (ASH), said the self-paced pathway is a much-needed option, particularly the immediate feedback on test questions. “For years, ASH has been advocating that ABIM move from the traditional sit-down testing to an alternative form of ‘formative’ assessment that has been adapted by other specialty boards,” Dr.

CMS Expands Access to CAR T-Cell Therapies Nationwide
https://www.ashclinicalnews.org/online-exclusives/cms-expands-access-car-t-cell-therapies-nationwide/

Aug 16th, 2019 - The Centers for Medicare and Medicaid Services (CMS) will now provide “consistent and predictable” nationwide access to chimeric antigen receptor (CAR) T-cell therapies, according to CMS Administrator Seema Verma. This decision comes in the wake of last week’s announcement that CMS was increasing payments for CAR T-cell therapies from 50 percent to 65 percent. Prior to this announcement, Medica...

Highlights in Geriatric Hematology From the ASH Annual Meeting & Exposition
https://ascopost.com/issues/august-10-2019/highlights-in-geriatric-hematology-from-the-ash-annual-meeting-exposition/

Aug 9th, 2019 - GUEST EDITOR Stuart M. Lichtman, MD, FACP, FASCO Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and Professor of Medicine at Weill Cornell Medical College, New York....

ASH Honors Richard Aster, MD, With the Wallace H. Coulter Award for Lifetime Achievement in Hematology
https://ascopost.com/issues/august-10-2019/ash-honors-richard-aster-md/

Aug 9th, 2019 - Richard Aster, MD The American Society of Hematology (ASH) will recognize Richard Aster, MD, of the Medical College of Wisconsin and Versiti Blood Center of Wisconsin in Milwaukee with the 2019 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Aster will be honored for his significant contributions to hematology through research, mentorship, and education throughout his 62-ye...

CMS Increases Payment, Access to CAR T-Cell Therapy
https://www.ashclinicalnews.org/online-exclusives/medicare-increases-payments-car-t-cell-therapy/

Aug 9th, 2019 - The Centers for Medicare and Medicaid Services (CMS) announced two policy changes that should improve access to chimeric antigen receptor (CAR) T-cell therapies: First, the agency issued a final rule that raises payments for new technologies, including CAR T-cell therapies, from 50% to 65%. Next, CMS Administrator Seema Verma said that CMS will now provide “consistent and predictable” nationwid...

Treatment of Pediatric Venous Thromboembolism.
https://doi.org/10.12788/jhm.3246
Journal of Hospital Medicine; Meier KA, Tarango C

Aug 6th, 2019 - American Society of Hematology 2018 Guidelines for the management of venous thromboembolism: treatment of pediatric venous thromboembolism DEVELOPER: The American Society of Hematology multidisciplinary subcommittee RELEASE DATE: November 27, 2018 FUNDING SOURCE: American Society of Hematology PRIOR VERSION: N/A TARGET POPULATION: less than 18 years of age.

ASH Backs Palliative Blood Transfusions During Hospice Care, Announces 2019 Honorific and Mentor Award Recipients, and more
https://www.ashclinicalnews.org/news/ash-directions/ash-backs-palliative-blood-transfusions-hospice-care-announces-2019-honorific-mentor-award-recipients/

Aug 1st, 2019 - ASH Backs the Use of Palliative Blood Transfusions During Hospice Care for Symptom Improvement The American Society of Hematology (ASH) has announced its support of palliative blood transfusions during end-of-life care in a recent policy statement. The Medicare hospice benefit for patients undergoing end-of-life care focuses on maximizing quality of life by providing comfort and support service...

ICYMI: Ibrutinib/rituximab combo improves CLL survival
https://www.mdedge.com/hematology-oncology/article/205472/cll/icymi-ibrutinib/rituximab-combo-improves-cll-survival?channel=59374
Lucas Franki

Jul 31st, 2019 - Patients with previously untreated chronic lymphocytic leukemia (CLL) aged 70 years or younger who received ibrutinib/rituximab therapy experienced significantly greater progression-free survival, compared with those who received standard chemotherapy with fludarabine, cyclophosphamide, and rituximab (89. 4% vs.

Tumour flare reaction in cancer treatments: a comprehensive literature review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749970
Anti-cancer Drugs; Taleb B A

Jul 27th, 2019 - In the past decade, tumour flare reaction (TFR) was considered as a new side effect associated with immunomodulatory agents (IMiDs) and as a condition of chronic lymphocytic leukaemia (CLL). However, this phenomenon is also observed with immune checkpoint inhibitors in solid tumours. It is still poorly understood and its incidence is underestimated. TFR has been associated with morbidity, there...

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
https://ascopost.com/issues/july-25-2019/fda-approves-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma/

Jul 24th, 2019 - On June 27, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The application received approval through the FDA’s Real-Time Oncology Review pilot program. The approval is based on results f...

New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more
https://www.ashclinicalnews.org/news/ash-directions/new-ash-congressional-fellow-accepting-submissions-2019-ash-annual-meeting/

Jul 1st, 2019 - Zachary Kiser, PhD Next ASH Congressional Fellow Is Bound for Capitol Hill Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the next ASH Congressional Fellow. Dr. Kiser, a post-doctoral fellow in the National Institutes of Health–funded Research Program at the University of Minnesota, will spend the 2019-2020 academic year in Washington, D.C., where he wil...

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma
https://ascopost.com/News/60199

Jun 26th, 2019 - Today, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The application received approval through the FDA’s Real-Time Oncology Review pilot program. The approval is based on results from t...

The use of direct oral anticoagulants for extended duration thromboprophylaxis in medic...
https://doi.org/10.1007/s11239-019-01900-2
Journal of Thrombosis and Thrombolysis; Alshouimi RA, Al Rammah SM et. al.

Jun 21st, 2019 - The extended use of thromboprophylaxis with direct oral anticoagulants (DOACs) for more than 30 days has been evaluated as an alternative for the standard duration thromboprophylaxis (7-10 days) with low molecular weight heparin in medically ill patients to reduce the risk of venous thromboembolism (VTE) after hospital discharge. EMBASE and MEDLINE were searched for studies evaluating extended ...

Selected Abstracts From the 2019 ASCO Annual Meeting
https://ascopost.com/issues/june-10-2019/selected-abstracts-from-the-2019-asco-annual-meeting/

Jun 9th, 2019 - Plasma Cell Dyscrasias Syed Ali Abutalib, MD Ola Landgren, MD, PhD To complement The ASCO Post’s comprehensive coverage of the 2019 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for plasma cell dyscrasias, particularly multiple myeloma. For full details of these study abstracts, visit http://abstracts.asco.org. ABSTR...

Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More
https://www.ashclinicalnews.org/news/the-society-pages/remembering-milton-h-freedman-caryn-lerman-named-director-usc-norris/

Jun 1st, 2019 - Remembering Milton H. Freedman (1919 – 2019) Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21, 2019. Dr. Freedman was born in Atlanta, where he spent almost his entire life, except for a stint in the U.S. Navy as a flight surgeon during World War II and a hematology fellowship at Pratt Diagnostic Hospital (now Tufts Medical Center) in Bost...

Evolving paradigm in thrombophilia screening.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687403
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis; Ashraf N, Visweshwar N et. al.

May 30th, 2019 - : The role of genetic thrombophilia screening for identifying a hypercoagulable state in the management of venous thromboembolism. We searched MEDLINE and EMBASE from 1995 to 2017, the websites of the professional bodies including American Society of Hematology, British Society of Hematology, International Society of Thrombosis and Hemostasis, College of American Pathologists, American College ...

Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-...
https://doi.org/10.1097/PPO.0000000000000379
Cancer Journal (Sudbury, Mass.); Shah UA, Smith EL

May 28th, 2019 - Multiple myeloma is still an incurable malignancy despite the many new therapies approved over the last decade and therefore represents a significant unmet medical need. To address this need, adoptive cellular therapies using chimeric antigen receptor (CAR) T-cells are being explored in clinical investigations. The number of CAR T-cell trials for multiple myeloma has increased exponentially ove...

Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible...
https://doi.org/10.1016/j.clml.2019.04.009
Clinical Lymphoma, Myeloma & Leukemia; Cao Y, Wan N et. al.

May 27th, 2019 - Many new regimens have been applied to newly diagnosed transplant-ineligible multiple myeloma, but no head-to-head research has been performed to compare the efficacy of these treatments. Currently lenalidomide plus dexamethasone (Rd) is one of the standard treatments. Our aim was to make a comparison of these treatments to Rd by a network meta-analysis. We performed a systematic review and net...

Debating the Role of Opioids in the Management of Chronic Cancer Pain
https://ascopost.com/issues/may-25-2019/debating-the-role-of-opioids-in-the-management-of-chronic-cancer-pain/

May 24th, 2019 - A Conversation With Leslie J. Blackhall, MD, and Charles F. von Gunten, MD, PhD Despite the increasing public awareness of the danger of the overuse of prescription opioids, drug overdose deaths continue to rise in the United States. According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2017, nearly 400,000 people died of an overdose involving opioids, including both p...

Charles G. Mullighan, MBBS (Hons), MSc, MD, Named St. Jude Comprehensive Cancer Center Deputy Director
https://ascopost.com/issues/may-25-2019/charles-mullighan-named-st-jude-comprehensive-cancer-center-deputy-director/

May 24th, 2019 - The St. Jude Children’s Research Hospital Comprehensive Cancer Center has appointed Charles G. Mullighan, MBBS (Hons), MSc, MD, as its new Deputy Director. In this new position, Dr. Mullighan will help guide precision medicine and preclinical strategic research initiatives for the Center, which is the nation’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted s...